CTICasesDurvalumab-Induced Pneumonitis
Imaging findings
Chest CT shows bilateral, confluent ground-glass and consolidated opacities predominantly in the upper lung zones, overlapping with areas of evolving radiation fibrosis. Follow-up CT after withdrawal of the drug and initiation of low-dose steroids demonstrates complete resolution of these non-radiation-associated opacities.
Key takeaways
Durvalumab, an immune checkpoint inhibitor targeting PD-L1, can cause drug-induced pneumonitis or organizing pneumonia. It is critical to distinguish drug-induced lung toxicity from disease progression, radiation pneumonitis, or infection, as it rapidly responds to drug cessation and corticosteroid therapy.
AI-assisted summary — may contain errors. Verify against the source video. Learn more
More from this webinar
- Surgicel (Hemostatic Material) Mimicking Postoperative Mediastinal AbscessArtifact
- Bronchial Artery to Pulmonary Artery Shunt Mimicking Pulmonary EmbolismArtifact
- Waldenström Macroglobulinemia Associated Pulmonary Amyloidosis and Cystic Lung DiseaseMetabolic
- Intercostal Muscle Flap for Bronchial Stump Reinforcement Post-PneumonectomyArtifact
- Traumatic Thyroid HematomaTrauma
- Expiratory-Phase Contrast-Enhanced CT Accentuation of Mosaic Perfusion in Pulmonary HypertensionVascular
- Anomalous Subaortic Left Brachiocephalic VeinCongenital
- Onyx Embolic Material Mimicking Vascular Calcification or Foreign BodyArtifact
See all cases from June 25, 2021 →